PDF
Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy
Lin-Zhu Zhang1,2, Xu He3, Hai-Dong Zhu1,2(
)
PDF
Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy
)In a recent Nature elegant study, Wang et al. identified CD300ld, a novel functionally highly conserved tumor immunosuppressive receptor, highly expressed specifically on polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), as well as a key receptor in the regulation of recruitment and immunosuppressive function of PMN-MDSCs. Targeting CD300ld could remodel the tumor immune microenvironment, resulting in a broad-spectrum anti-tumor effect.
immunotherapy / neutrophil / tumor
| 1 | C Wang, X Zheng, J Zhang, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621(7980):830-839. |
| 2 | S Jaillon, A Ponzetta, D Di Mitri, A Santoni, R Bonecchi, A Mantovani. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485-503. |
| 3 | T Condamine, V Kumar, IR Ramachandran, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014;124(6):2626-2639. |
| 4 | F Borrego. The CD300 molecules: an emerging family of regulators of the immune system. Blood. 2013;121(11):1951-1960. |
| 5 | R Kim, A Hashimoto, N Markosyan, et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022;612(7939):338-346. |
/
| 〈 |
|
〉 |
AI Summary
